MDxHealth SA (MDXH) vs Precipio (PRPO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precipio (PRPO) has outperformed MDxHealth SA (MDXH) over the past year, gaining 26.4% versus a loss of 87.2%. MDxHealth SA is the larger company by market cap ($55.1 million vs $42.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXH | PRPO |
|---|---|---|
| Share price | $0.577 | $23.47 |
| Market cap | $55.06M | $42.02M |
| 1-day change | -0.60% | +1.21% |
| YTD return | -83.74% | +0.91% |
| 1-year return | -87.16% | +26.38% |
| 5-year return | — | -54.71% |
| Forward P/E | — | 60.18 |
| EPS (TTM) | $-0.70 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.33 | $33.63 |
| 52-week low | $0.40 | $16.40 |
| Distance from 52-week high | -89.17% | -30.21% |
| Analyst consensus | none | — |
| Avg. price target upside | +211.96% | — |
| Average volume | 5.69M | 127.60K |
| Shares outstanding | 95.42M | 1.79M |
| Employees | 364 | 61 |
| Sector | Health Care | Industrials |
| Industry | Medical Specialities | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRPO has outperformed MDXH by 113.5 percentage points over the past year.
- The two companies sit in different sectors: MDxHealth SA in Health Care and Precipio in Industrials.
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Health Care · Medical Specialities · 364 employees
About Precipio
PRPO stock →Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 61 employees
MDXH vs PRPO FAQ
Which is bigger, MDxHealth SA or Precipio?
MDxHealth SA (MDXH) is larger, with a market capitalization of $55.06M compared with $42.02M for Precipio (PRPO).
Which stock has performed better over the past year, MDXH or PRPO?
PRPO returned +26.38% over the past 12 months, compared with -87.16% for MDXH (price return, excluding dividends). Past performance does not predict future results.
Are MDxHealth SA and Precipio in the same industry?
No. MDxHealth SA is in the Health Care sector, while Precipio is in Industrials.